Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Toni Choueiri, MD
With
Beth Israel Deaconess Medical Center
Subjects will receive an intravenous infusion of Avastin on Day 1 and Day 15 of each month (cycle). Subjects will take a daily oral dose of BKM-120 at the dose level assigned.
Subjects will have a clinic visit weekly during Cycle 1 and then on Day 1 and Day 15 of each cycle for blood tests and physical exam.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Metastatic RCC with clear cell component or papillary RCC
Life expectancy \> 12 weeks
Must have failed at least 1 prior anti-VEGF systemic therapy for metastatic RCC
You may not be if
Prior treatment with a P13K inhibitor or bevacizumab
Untreated brain metastases
Acute or chronic liver or pancreatic disease
Major mood disorder
Concurrent severe and/or uncontrolled medical condition
Diabetes mellitus
GI disease
Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
Pregnant or breastfeeding
HIV positive
History of another malignancy within 3 years except cured basal cell carcinoma of the skin or excised in situ carcinoma of the cervix
